Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAILY: Lifestyle Changes, Aspirin, and Vitamin D in Colorectal Cancer with Minimal Residual Disease
NCT05036109Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2021
- Primary completion
- Feb 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Open-label, single-arm trial of aspirin and vitamin d in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: ctDNA clearance rate at 1 year. Started Oct 2021; status: completed.
02
Drugs
aspirinvitamin d
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05036109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05036109.